Sotyktu (deucravacitinib) - BMS
Clinical Outcomes at Week 52 in Male and Female Patients With PsA Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2289; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available 
Clinical data • P3 data • Retrospective data • Ankylosing Spondylitis • Immunology • Psoriasis • Psoriatic Arthritis • Rheumatology • Spondylarthritis
https://eppro02.ativ.me/web/page.php?nav=false&page=Session&project=ACR26&id=3570064
 
Lihi Eder, MD, PhD
 
Sep 8, 2026
 
Prev Next